Galera Therapeutics, Inc.

Galera Therapeutics (GRTX) shows no cyber incidents or material red-flag 8-K filings in our 90-day monitoring window, suggesting operational stability in the recent period. However, the absence of near-term signals does not indicate overall risk profile; biotech companies face persistent dilution pressures and financing volatility that require deeper historical context. The full $49 Report extends analysis across 12 months of SEC filings, quantifies shareholder dilution risk, maps capital raise patterns, and flags AI-detected risk signals missed by standard screening. The full $49 Report adds dilution trajectory scoring, 12-month 8-K context, financing history analysis, and machine-detected anomalies.